Greenwich LifeSciences, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2019 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Greenwich LifeSciences, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2019 to Q2 2024.
  • Greenwich LifeSciences, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$2.61M, a 60.1% decline year-over-year.
  • Greenwich LifeSciences, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$10.2M, a 15.3% decline year-over-year.
  • Greenwich LifeSciences, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$8.89M, a 13.6% decline from 2022.
  • Greenwich LifeSciences, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$7.83M, a 71.2% decline from 2021.
  • Greenwich LifeSciences, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$4.57M, a 145% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$10.2M -$2.61M -$978K -60.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$9.24M -$2.47M -$348K -16.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-14
Q4 2023 -$8.89M -$2.75M +$43.8K +1.57% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-15
Q3 2023 -$8.94M -$2.39M -$72.8K -3.14% Jul 1, 2023 Sep 30, 2023 10-Q 2023-10-19
Q2 2023 -$8.86M -$1.63M -$882K -118% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$7.98M -$2.12M -$155K -7.88% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-14
Q4 2022 -$7.83M -$2.79M -$430K -18.2% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-15
Q3 2022 -$7.4M -$2.32M -$1.46M -169% Jul 1, 2022 Sep 30, 2022 10-Q 2023-10-19
Q2 2022 -$5.94M -$746K +$3.67K +0.49% Apr 1, 2022 Jun 30, 2022 10-Q 2023-10-19
Q1 2022 -$5.94M -$1.97M -$1.37M -230% Jan 1, 2022 Mar 31, 2022 10-Q 2023-10-19
Q4 2021 -$4.57M -$2.36M -$1.21M -105% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 -$3.36M -$863K -$606K -236% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$2.75M -$750K -$539K -256% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-14
Q1 2021 -$2.22M -$597K -$352K -144% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-14
Q4 2020 -$1.86M -$1.15M -$814K -242% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-21
Q3 2020 -$1.05M -$257K +$79.1K +23.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$1.13M -$210K +$2.39M +91.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-15
Q1 2020 -$3.52M -$245K -$95.9K -64.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-15
Q4 2019 -$3.43M -$337K Oct 1, 2019 Dec 31, 2019 10-K 2021-03-31
Q3 2019 -$336K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 -$2.6M Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-16
Q1 2019 -$149K Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.